TE_36592
Basic information Differential Expression Stage analysis Survival analysis Correlation analysis| TE family | MLT2B3 |
|---|---|
| TE superfamily | ERV3 |
| TE order | LTR |
| Gene | ENSG00000229289, - |
| Class | Chimeric, Intergenic |
| Coding | Non-coding |
| Tumor-specific score | 294.17 |
| Counts of samples | TCGA_tumor:260; TCGA_normal:0; GTEx:0 |
| TSS | chr21(+):18950219 |
Transcript isoforms
| Transcript_ID | Gene | Class | Coding | ORF | Position |
|---|---|---|---|---|---|
| teRNA_36592.1 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18972191 |
| teRNA_36592.2 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18975217,19023433,19023453 |
| teRNA_36592.3 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18976723,19003631,19003651 |
| teRNA_36592.4 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18976723,18997628,18997648 |
| teRNA_36592.5 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18975217,19003631,19003651 |
| teRNA_36592.6 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18972171,18976723,19023433,19023453 |
| teRNA_36592.7 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18959518,18959538 |
| teRNA_36592.8 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,19023433,19023453 |
| teRNA_36592.9 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,18966277,18966377,18972171,18972191 |
| teRNA_36592.10 | - | Intergenic | Non-coding | Non-coding | chr21(+):18950220,18950460,19034078,19034149,19051709,19051788,19065997,19066017 |
1
2
GTEx
The proportion of samples in which the TE-initiated transcript was expressed across 46 body sites in the Genotype-Tissue Expression (GTEx) project.
TCGA
The proportion of samples in which the TE-initiated transcript was expressed across 33 cancer types from The Cancer Genome Atlas (TCGA).
GTEx
The expression of TE-initiated transcript across 46 body sites from The Genotype-Tissue Expression (GTEx) project.
